---
id: 225
title: Viral Encephalitis
category: clinical_syndromes
subcategory: central_nervous_system
tags: [encephalitis, HSV, West-Nile-virus, acyclovir, CSF, MRI, EEG]
difficulty: high
---

## Question

How is viral encephalitis managed? Use **"Altered Mental Status + Fever → LP + MRI + EEG, Empiric Acyclovir × 14-21d (HSV)"** framework.

## Answer

### **Definition:**

**Encephalitis:**
- **Brain parenchymal inflammation** → altered mental status, seizures, focal neurologic deficits

**vs. Meningitis:**
- **Meningitis:** Meningeal inflammation (headache, neck stiffness, NO altered mental status)
- **Encephalitis:** Brain inflammation (altered mental status, seizures, focal deficits)

### **Clinical Presentation:**

**Classic Triad:**
1. **Fever**
2. **Altered mental status** (confusion, lethargy, coma)
3. **Focal neurologic deficits** OR **seizures**

**Other Features:**
- **Headache** (80%)
- **Behavioral changes, personality changes**
- **Movement disorders** (tremor, ataxia, parkinsonism)
- **Aphasia** (if temporal lobe involvement)

### **Etiology:**

**Most Common:**
- **HSV-1** (10-20% of identified cases, most common sporadic viral encephalitis)
- **Varicella-zoster virus (VZV)**
- **Enteroviruses** (especially children)
- **West Nile virus** (seasonal, summer/fall)
- **Arboviruses:** Eastern equine encephalitis (EEE), La Crosse, St. Louis encephalitis

**Immunocompromised:**
- **CMV, HHV-6, JC virus (PML)**

**Other:**
- **Rabies, mumps, measles, influenza**
- **Autoimmune encephalitis** (anti-NMDA receptor, anti-LGI1) - mimics viral encephalitis

### **Diagnosis:**

**CSF Analysis (Lumbar Puncture):**

**Typical Viral Encephalitis CSF:**
- **WBC:** 10-500 (lymphocytic predominance, >80%)
- **Protein:** ↑ (50-150 mg/dL)
- **Glucose:** Normal (or mildly ↓)
- **Opening pressure:** Normal or mildly elevated

**HSV Encephalitis CSF (May Have):**
- **RBCs** (hemorrhagic necrosis of temporal lobes)
- **Xanthochromia**

**CSF PCR (ESSENTIAL):**
- **HSV-1/2 PCR** (sensitivity 95-100%)
- **VZV PCR**
- **Enterovirus PCR**
- **West Nile virus IgM** (CSF + serum)

**Imaging:**

**MRI Brain with Contrast (PREFERRED):**
- **HSV:** Temporal lobe involvement (bilateral, asymmetric), insular cortex, cingulate gyrus
- **West Nile:** Basal ganglia, thalamus, brainstem
- **VZV:** Multifocal white matter lesions
- **Anti-NMDA receptor:** Nonspecific or normal

**CT Brain:**
- **Less sensitive** (may miss early changes)
- **Use if MRI not available**

**EEG:**
- **Abnormal in 80%** (diffuse slowing, focal abnormalities)
- **HSV:** Periodic lateralized epileptiform discharges (PLEDs) in temporal lobes (50%)
- **Helps detect non-convulsive seizures**

### **Treatment:**

**Empiric Therapy (Start IMMEDIATELY, Do NOT Wait for CSF Results):**

**Acyclovir 10 mg/kg IV q8h × 14-21 days** (for HSV)
- **Start empirically** in all suspected encephalitis (until HSV ruled out)
- **Do NOT delay** (mortality 70% if untreated HSV, 20% if treated)

**Pathogen-Specific Therapy:**

**HSV Encephalitis:**
- **Acyclovir 10 mg/kg IV q8h × 14-21 days**
- **Check renal function** (acyclovir nephrotoxicity)
- **Adequate hydration**

**VZV Encephalitis:**
- **Acyclovir 10-15 mg/kg IV q8h × 14-21 days**
- **Higher dose** than HSV

**CMV Encephalitis (Immunocompromised):**
- **Ganciclovir 5 mg/kg IV q12h** + **foscarnet 90 mg/kg IV q12h** × 21 days (or until CSF PCR negative)

**West Nile Virus, Enteroviruses, Arboviruses:**
- **Supportive care only** (no specific antiviral)

**Autoimmune Encephalitis:**
- **IVIG, corticosteroids, plasma exchange**
- **Remove underlying trigger** (tumor, e.g., ovarian teratoma in anti-NMDA receptor encephalitis)

### **Supportive Care:**

**Seizure Management:**
- **Antiepileptic drugs** (levetiracetam, fosphenytoin)
- **Status epilepticus:** Lorazepam, phenytoin, consider intubation

**ICP Management:**
- **Elevate head of bed 30°**
- **Mannitol, hypertonic saline** (if ↑ICP)
- **Avoid hypotonic fluids**

**ICU Monitoring:**
- **If severe:** GCS ≤8, refractory seizures, increased ICP

### **Prognosis:**

**HSV Encephalitis:**
- **Mortality:** 20-30% (even with treatment)
- **Neurologic sequelae:** 40-60% (cognitive impairment, seizures, memory deficits)
- **Better outcomes** if treatment started early (<48h)

**West Nile Virus:**
- **Mortality:** 10-15% (neuroinvasive disease)
- **Flaccid paralysis** (10-20%, polio-like syndrome, often permanent)

### **Differential Diagnosis:**

**Non-Infectious:**
- **Autoimmune encephalitis** (anti-NMDA receptor, anti-LGI1, anti-VGKC)
- **Paraneoplastic encephalitis**
- **Acute disseminated encephalomyelitis (ADEM)**

**Infectious (Non-Viral):**
- **Bacterial meningitis** (treat empirically with ceftriaxone + vancomycin until CSF results)
- **TB meningitis, cryptococcal meningitis** (if immunocompromised)
- **Brain abscess, toxoplasmosis**

**Metabolic/Toxic:**
- **Hepatic encephalopathy, uremic encephalopathy**
- **Drug intoxication, withdrawal**

## Key Points

### **Altered Mental Status + Fever = Encephalitis:**
- **Differentiate from meningitis** (meningitis = no AMS)

### **Empiric Acyclovir IMMEDIATELY:**
- **10 mg/kg IV q8h × 14-21 days** (for HSV)
- **Do NOT wait for CSF results** (mortality 70% if untreated)

### **LP + MRI + EEG:**
- **CSF PCR:** HSV, VZV, enterovirus, WNV
- **MRI:** Temporal lobe (HSV), basal ganglia (WNV)
- **EEG:** PLEDs (HSV), detect non-convulsive seizures

### **HSV Most Common Sporadic:**
- **Temporal lobe involvement** (bilateral, asymmetric)
- **Hemorrhagic necrosis** (RBCs in CSF)

### **No Specific Treatment for West Nile, Enteroviruses:**
- **Supportive care only**

### **Clinical Pearls:**
- **Altered mental status + fever** → LP + MRI + EEG, empiric acyclovir 10 mg/kg IV q8h
- **Do NOT wait for CSF results** (start acyclovir immediately)
- **HSV:** Temporal lobe involvement (MRI), PLEDs (EEG), RBCs in CSF
- **Duration:** 14-21 days IV acyclovir
- **West Nile:** Basal ganglia, flaccid paralysis (supportive care only)
- **Consider autoimmune encephalitis** (anti-NMDA receptor, especially young women)

## Sources

- [IDSA: Encephalitis Guidelines 2024]
- [NEJM: Viral Encephalitis 2024]

## Media

N/A
